The HCPLive hospital medicine page is a comprehensive resource for clinical news and insights on the emergency medicine specialty. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for emergent care, and more.
May 15th 2024
A post hoc analysis from FIDELITY shows finerenone could significantly reduce eGFR slopes among patients at risk of worsening CKD due to a heart failure hospitalization.
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
When Cataract Surgeries Resumed in 2020, Complications Decreased
June 21st 2022Investigators presented the study at the Netherlands Ophthalmological Society Annual Congress, noting a potential cause for this trend could be the heightened cautiousness of surgical teams following the 2 month intermission due to the COVID-19 pandemic.
Study Provides Novel Insight on OUD Diagnosis Factors in Opioid-Naive Patients
May 19th 2022Presence of chronic liver disease, prior use of gabapentin and being discharged to a long-term hospital or rehabilitation center are among some of the factors associated with a new opioid use disorder diagnosis.
Phase 3 Data Show Isatuximab Offers Progression Free Survival for Multiple Myeloma
May 17th 2022Isatuximab in combination with carfilzomib and dexamethasone (Kd) demonstrate the longest median progression free survival (mPFS) on a proteasome inhibitor backbone in multiple myeloma patients who relapsed after a prior therapy, including lenalidomide.